Investigating the role of ARC in hematopoiesis and myeloproliferative neoplasms

研究 ARC 在造血和骨髓增殖性肿瘤中的作用

基本信息

  • 批准号:
    8783051
  • 负责人:
  • 金额:
    $ 4.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-15 至 2016-07-14
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): During hematopoiesis, descendants of hematopoietic stem cells (HSCs) become committed to differentiate along specific cell lineages, eventually acquiring the characteristics of mature terminally differentiated cells. The identification and isolation of HSCs has advanced substantially over the past few decades, however, the mechanisms that regulate stem cell lineage commitment and differentiation are still obscure. Programmed cell death plays a crucial role in the regulation of normal hematopoietic differentiation, and this cellular process is frequently altered in hematologic malignancies. In Philadelphia chromosome negative myeloproliferative neoplasms (Ph- MPN), dysregulation of cell death pathways is frequently observed, implicating cell death proteins as potential factors in the pathogenesis of disease and targets for therapeutic intervention. Currently the molecular pathogenesis of Ph- MPNs is largely unknown. Recent studies have highlighted the importance of the anti-apoptotic protein apoptosis repressor with caspase recruitment domain (ARC) in human malignancies, however, the function of ARC in normal and malignant hematopoiesis has not been thoroughly investigated. Our work aims to identify the role of ARC in mouse and human hematopoietic stem and progenitor cells (HSPCs), and in the Ph- MPN primary myelofibrosis (PMF). Utilizing an ARC knockout (ARC [-/-]) mouse model for our investigation, we have found that aged ARC [-/-] mice exhibit significantly altered blood cell counts and splenomegaly with an expansion of myeloid and immature cells consistent with extramedullary hematopoiesis. ARC [-/-] bone marrow revealed reduced blood sinusoids and increased bone marrow fibrosis according to reticulin staining. Further analysis showed expansion of the bone marrow HSC compartment and in vitro methylcellulose colony assays revealed altered HSC differentiation capacity. The hematologic findings in ARC [-/-] mice are consistent with a novel mouse model of PMF. Additionally, the ARC [-/-] phenotype is transplantable into lethally irradiated congenic recipients. We hypothesize that ARC plays a critical role in mouse and human HSPC function and that loss of ARC may contribute to the pathogenesis of PMF. To characterize ARC in lineage commitment and differentiation of mouse and human HSPCs, we will utilize genetic murine models, stem cell transplantation, in vitro stem cell functional assays and in vivo xenotransplantation experiments. To elucidate the mechanism of ARC in HSCs, we will use transcriptional profiling to guide our investigation and identify molecular pathways critical to ARC function. Furthermore, we will quantitate ARC transcript levels in HSCs from patients with PMF to determine if ARC expression is relevant to the disease pathogenesis. PMF has the most severe morbidity and greatest mortality of the Ph-MPNs and the identification of novel mouse models and potential therapeutic targets is urgently required.
描述(申请人提供):在造血过程中,造血干细胞(HSCs)的后代致力于沿着特定的细胞谱系分化,最终获得成熟的终末分化细胞的特征。在过去的几十年里,造血干细胞的鉴定和分离已经取得了很大的进展,然而,调控干细胞谱系承诺和分化的机制仍然不清楚。程序性细胞死亡在调节正常的造血细胞分化中起着至关重要的作用,而这一细胞过程在血液系统恶性肿瘤中经常发生改变。在费城染色体阴性的骨髓增生性肿瘤(Ph-MPN)中,细胞死亡途径的异常经常被观察到,这意味着细胞死亡蛋白是潜在的 疾病的发病机制和治疗干预的目标。目前,Ph-MPNS的分子发病机制尚不清楚。最近的研究强调了带有半胱氨酸天冬氨酸酶招募结构域(ARC)的抗凋亡蛋白在人类恶性肿瘤中的重要性,然而,ARC在正常和恶性造血中的作用还没有得到深入的研究。我们的工作旨在确定ARC在小鼠和人类造血干细胞和祖细胞(HSPC)中的作用,以及在Ph-MPN原发骨髓纤维化(PMF)中的作用。利用ARC基因敲除(ARC[-/-])小鼠模型进行研究,我们发现老年ARC[-/-]小鼠表现出显著的血细胞计数变化和脾肿大,髓系细胞和未成熟细胞的扩张与髓外造血相一致。根据网织蛋白染色,ARC[-/-]骨髓显示血窦减少,骨髓纤维化增加。进一步分析显示,骨髓HSC间隔室扩大,体外甲基纤维素集落检测显示HSC分化能力改变。ARC[-/-]小鼠的血液学发现与一种新的PMF小鼠模型一致。此外,ARC[-/-]表型可以移植到致死性照射的同源受体中。我们推测ARC在小鼠和人类HSPC功能中起关键作用,ARC的缺失可能参与PMF的发病。为了确定ARC在小鼠和人类HSPC的谱系承诺和分化中的特征,我们将利用遗传小鼠模型、干细胞移植、体外干细胞功能分析 体内异种移植实验。为了阐明ARC在HSCs中的作用机制,我们将使用转录图谱来指导我们的研究,并确定对ARC功能至关重要的分子途径。此外,我们将定量检测PMF患者HSC中ARC转录水平,以确定ARC表达是否与疾病发病机制有关。PMF是Ph-MPN中发病率最高、死亡率最高的疾病,迫切需要寻找新的小鼠模型和潜在的治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Stanley其他文献

Robert Stanley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Stanley', 18)}}的其他基金

Investigating the role of ARC in hematopoiesis and myeloproliferative neoplasms
研究 ARC 在造血和骨髓增殖性肿瘤中的作用
  • 批准号:
    8900799
  • 财政年份:
    2014
  • 资助金额:
    $ 4.77万
  • 项目类别:
Investigating the role of ARC in hematopoiesis and myeloproliferative neoplasms
研究 ARC 在造血和骨髓增殖性肿瘤中的作用
  • 批准号:
    9172478
  • 财政年份:
    2014
  • 资助金额:
    $ 4.77万
  • 项目类别:

相似国自然基金

基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
  • 批准号:
    82302715
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
  • 批准号:
    31200592
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
  • 批准号:
    24K10442
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
  • 批准号:
    23K15297
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Fanconi anemia経路に着目したiPS細胞における高レベル複製ストレスの原因解明
阐明 iPS 细胞中高水平复制应激的原因,重点关注范可尼贫血途径
  • 批准号:
    23K14452
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Analysis of the mechanism of hemolytic anemia in canine babesiosis and development of novel therapeutic measures
犬巴贝斯虫病溶血性贫血机制分析及新治疗措施开发
  • 批准号:
    23KJ0074
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Brain blood flow, oxygenation, and cognition in adult onset iron deficiency anemia
成人缺铁性贫血的脑血流量、氧合和认知
  • 批准号:
    10735765
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Chromatin State Alterations in Fanconi Anemia Hematologic Disease and Bone Marrow Failure
范可尼贫血血液疾病和骨髓衰竭中的染色质状态改变
  • 批准号:
    10735366
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Liver-Gut Axis in Neonatal Anemia and Its Role in RBC Transfusion Associated Gut Injury
新生儿贫血中的肝肠轴及其在红细胞输注相关肠道损伤中的作用
  • 批准号:
    10583807
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Small Molecule Therapeutics for Sickle Cell Anemia
镰状细胞性贫血的小分子疗法
  • 批准号:
    10601679
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Accuracy and Feasibility of Non-Invasive Anemia Screening Assistant (ASIST) Device in Resource-Limited Settings
资源有限环境中非侵入性贫血筛查辅助 (ASIST) 设备的准确性和可行性
  • 批准号:
    10575222
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Mobile phone-based screening for anemia in young children in western Kenya
基于手机的肯尼亚西部幼儿贫血筛查
  • 批准号:
    10752968
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了